Maggiore G, Bernard O, Homberg J C, Hadchouel M, Alvarez F, Hadchouel P, Odièvre M, Alagille D
J Pediatr. 1986 Mar;108(3):399-404. doi: 10.1016/s0022-3476(86)80880-0.
In the past 10 years we have examined 20 children with inflammatory liver disease associated with high serum titers of anti-liver-kidney microsome antibody (anti-LKM). The first hepatic symptoms were progressive fatigue and jaundice, the fortuitous finding of hepatomegaly or splenomegaly with raised transaminase activity, or an acute hepatitis-like illness. At the time of diagnosis, hepatomegaly was present in 18 children, splenomegaly in 16, jaundice in nine, and ascites in two. Serum alanine transferase activities were elevated in all but two, who had already received steroids. Serum total gammaglobulin values were greater than 2.0 gm/dl in 16 children, prothrombin activity less than or equal to 60% in six, and serum titer of anti-LKM between 1:100 and 1:100,000. All children but one had cirrhosis, and histologic signs of aggressivity were present in 14. In 11 children one or more extrahepatic diseases were present, including type 1 diabetes, vitiligo, glomerulonephritis, autoimmune hemolytic anemia, hypoglycemia with hyperinsulinism, autoimmune thyroiditis, chronic mucocutaneous candidiasis with hypoparathyroidism, and multiple cutaneous and visceral telangiectasias. Treatment with prednisone and azathioprine improved the liver condition in 16 of the 18 patients given treatment. In eight of them discontinuation of treatment resulted in rapid relapse; 14 are still receiving treatment and have stable hepatic function with follow-up from 8 months to 6 1/2 years. Only two are free of treatment. Four children died, two in spite of immunosuppressive therapy, one during a relapse, and one of extrahepatic disease. These results indicate that this autoimmune inflammatory liver disease may have onset early in life, with several clinical patterns; is frequently associated with certain types of extrahepatic manifestations of autoimmune origin; and is a potentially fatal disease for which immunosuppressive treatment must be started early.
在过去10年里,我们检查了20名患有炎症性肝病且血清抗肝肾微粒体抗体(抗-LKM)滴度高的儿童。最初的肝脏症状为进行性疲劳和黄疸,偶然发现肝肿大或脾肿大伴转氨酶活性升高,或类似急性肝炎的疾病。诊断时,18名儿童有肝肿大,16名有脾肿大,9名有黄疸,2名有腹水。除两名已接受类固醇治疗的儿童外,所有儿童的血清丙氨酸转氨酶活性均升高。16名儿童的血清总γ球蛋白值大于2.0 g/dl,6名儿童的凝血酶原活性小于或等于60%,抗-LKM血清滴度在1:100至1:100,000之间。除一名儿童外,所有儿童均有肝硬化,14名有侵袭性组织学征象。11名儿童有一种或多种肝外疾病,包括1型糖尿病、白癜风、肾小球肾炎、自身免疫性溶血性贫血、高胰岛素血症伴低血糖、自身免疫性甲状腺炎、慢性黏膜皮肤念珠菌病伴甲状旁腺功能减退,以及多发性皮肤和内脏毛细血管扩张。接受泼尼松和硫唑嘌呤治疗的18名患者中有16名肝脏状况得到改善。其中8名患者停药后迅速复发;14名仍在接受治疗,肝功能稳定,随访时间为8个月至6年半。只有两名患者无需治疗。4名儿童死亡,两名尽管接受了免疫抑制治疗仍死亡,一名在复发期间死亡,一名死于肝外疾病。这些结果表明,这种自身免疫性炎症性肝病可能在生命早期发病,有多种临床模式;常与某些自身免疫性起源的肝外表现相关;是一种潜在致命疾病,必须尽早开始免疫抑制治疗。